Skip to main content

Welton Pharma

October 17, 2023
Franciscan C
Company Description: Welton Pharma is pre-clinical company developing our lead asset WP-038 for the treatment of colorectal cancer. Our patent-protected drug product is expected to increase the response rate in patients with colorectal cancer by ~300%. We have an experienced team with extensive manufacturing and regulatory experience, including a former FDA reviewer. We presently raising our $2.5M Seed round to advance our lead asset to IND-enabling studies.
Kevin Sill, CEO - Welton Pharma